Periodic Reporting for period 2 - mCUBE (Multi-omic data driven drug discovery and indication prioritisation platform in oncology)
Période du rapport: 2023-05-01 au 2024-07-31
More specifically, our team carried out the following activities:
- Development of AI-augmented pipelines for the data mapping and integration,
- Development of multi-omic data analysis pipelines for target discovery, biomarker discovery, patient selection and preclinical model selection,
- Integration and harmonization of omic data at scale,
- Implementation of a subset of these tools into a user-friendly cloud-based platform and deployment of the solution for our industrial partners, and
- Generation of scientific results using the different tools and pipelines developed with our academic partners.
We are developing mCUBE, an Artificial Intelligence (AI)-augmented cloud-based precision oncology platform for multi-omic, multi-cancer and multi-source data identification, aggregation and analysis. mCUBE encapsulates Epigene Labs’ deep expertise in oncology, data science, and bioinformatics into a user-friendly solution that will make a difference for cancer patients. Our solution delivers 3 main gains:
- increased productivity for our users (cancer scientists),
- increased profitability for our customers (biopharma companies), and
- improved care for cancer patients ultimately.
The conventional timeline for discovering a new target for a specific indication is 2 years. At Epigene, in the context of our first partnership with the Eyquem’s lab at UCSF, we not only rediscovered known antigens but also prioritised a list of promising targets for relapsed/refractory multiple myeloma in only 6 months. A few months later, in a second program focusing on colorectal and gastric cancer, this same task took only 3 months. Soon, thanks to the support of the EIC Accelerator, we will be able to tackle a new indication in only a few weeks.